Helicobacter Pylori Testing Market Size By Test (Invasive {Histology, Rapid Urease Test (RUT), HP Culture}, Non-Invasive {Serologic Test, Urea Breath Test (UBT), Stool Antigen Test (SAT)}, By Method (Point-of-Care (POC) Test, Laboratory Based Test), By En

Helicobacter Pylori Testing Market Size By Test (Invasive {Histology, Rapid Urease Test (RUT), HP Culture}, Non-Invasive {Serologic Test, Urea Breath Test (UBT), Stool Antigen Test (SAT)}, By Method (Point-of-Care (POC) Test, Laboratory Based Test), By End-use (Hospitals, Clinics, Diagnostic Laboratories), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 - 2032

The global helicobacter pylori testing market is likely to witness considerable growth through 2032, owing to a steadily expanding patient pool and the subsequently rising demand for point-of-care testing devices. These devices enable ease and accuracy of diagnosis at point-of-care facilities, augmenting market growth.

POC testing devices are specifically to designed to help physicians or clinicians take better decisions for disease management. For instance, the Pro Advantage H. Pylori Test Device has a rapid and simple test format to help physicians assess disease therapy. Meanwhile, shifting patient inclination towards minimally invasive test procedures are further outlining the industry scenario.

The overall helicobacter pylori testing market landscape is divided into segments such as test, method, end-use, and regional landscape.

Based on the test, the market is segmented into non-invasive and invasive tests. The non-invasive test segment is slated to grow considerably through 2032, fueled by their utilization in epidemiological surveys where endoscopy would not be suitable. These tests provide an alternate strategy for effective infection diagnosis without causing further discomfort to the patients. Non-invasive tests such as the urea breath test (UBT) yield accurate results and are suitable for monitoring the successful eradication of the infection.

On the basis of the method, the industry is classified into laboratory-based tests and point-of-care (POC) tests. The laboratory-based tests segment is expected to register considerable growth from 2023-2032, owing to the reliability and inexpensiveness of laboratory-based tests such as URINELISA for detecting h. pylori infection. Moreover, the high diagnostic accuracy associated with URINELISA warrants its use as a first-line screening tool to effectively diagnose h. Pylori infection in untreated patients.

Based on end-use, the industry is classified into clinics, hospitals, diagnostic labs, and others. Amongst them, the market size from the hospitals end-use segment is likely to cross more than USD 285 million by 2032. Segment growth can be attributed to the better availability of trained professionals, and rising occurrences of gastrointestinal diseases including duodenal ulcers, gastric cancer, and gastritis among others across developed economies. The growth can also be ascribed towards their ability to ensure effective diagnosis and rising world government spending towards the consolidation of the healthcare infrastructure.

Regionally, the industry is divided into Asia Pacific, Europe, North America, LATAM, and MEA. The North America helicobacter pylori testing market is set to expand substantially from 2023 to 2032, driven by the rising occurrences of the infection and increasing awareness about its diagnosis and treatment.

Nearly 30 to 40% of U.S. people are infected with H. pylori infection, which is likely to augment the industry scenario. The bacteria, which is known to increase the risk of stomach cancer, is further exacerbating the existing disease burden, and contributing to higher caseloads as well as associated mortality rates in the country.